These inhibitors include: erlotinib, an FDA approved reversible TKI indicated for the treatment of advanced NSCLC and pancreatic cancer, afatinib, a second generation irreversible ErbB family blocker also approved for the treatment of advanced NSCLC and pertuzumab, a monoclonal antibody that targets the extracellular region of HER2 preventing it from dimerizing with its other HER partners and approved for the treatment of HER2 amplified breast cancer in combination with trastuzumab [39-41]. Here, ERBB2 is linked to familial pancreatic carcinoma.